No­var­tis boasts a big new ad­van­tage for Cosen­tyx as da­ta in­di­cate the block­buster can mod­i­fy pso­ri­a­sis

No­var­tis got a big lead on the fast-chang­ing pso­ri­a­sis mar­ket when it grabbed an ap­proval for Cosen­tyx more than 18 months ago, putting it well ahead of ri­vals rush­ing through late-stage pro­grams. Now, the phar­ma gi­ant $NVS is look­ing to con­sol­i­date its hold on the lead role for new ther­a­pies with some re­mark­able da­ta sug­gest­ing the drug could act as a dis­ease mod­i­fi­er for a sig­nif­i­cant group of pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER